Gender differences in the association between antidepressant use and restless legs syndrome

Movement Disorders

Volumn 24, Issue 7, 2009, Pages 1054-1059

  Baughman, Kristin R ^a   Bourguet, Claire C ^a   Ober, Scott K ^b,c  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressants; Depression; Gender; Restless legs syndrome

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; MIRTAZAPINE; PAROXETINE; SERTRALINE; TRAZODONE; VENLAFAXINE;

ADULT; AGED; ARTICLE; DEPRESSION; DRUG USE; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; SEX DIFFERENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSERVATION; PRIMARY HEALTH CARE; REGRESSION ANALYSIS; RESTLESS LEGS SYNDROME; RISK FACTORS; SEX CHARACTERISTICS; VETERANS; YOUNG ADULT;

EID: 67651154472     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22517     Document Type: Article

References (32)

1. Picchietti D, Winkelman JW. Restless legs syndrome, periodic limb movements in sleep, and depression. Sleep 2005;28:891-898.
2. Bakshi R. Fluoxetine and restless legs syndrome. J Neurol Sci 1996;142:151-152.
3. Hargrave R, Beckley DJ. Restless leg syndrome exacerbated by sertraline. Psychosomatics 1998;39:177-178.
4. Perroud N, Lazignac C, Baleydier B, Cicotti A, Maris S, Damsa C. Restless legs syndrome induced by citalopram: a psychiatric emergency? Gen Hosp Psychiatry 2007;29:72-74.
5. Sanz-Fuentenebro FJ, Huidobro A, Tejadas-Rivas A. Restless legs syndrome and paroxetine. Acta Psychiatr Scand 1996;94: 482-484.
6. Prospero-Garcia KA, Torres-Ruiz A, Ramirez-Bermudez J, Velazquez-Moctezuma J, Arana-Lechuga Y, Teran-Perez G. Fluoxetine-mirtazapine interaction may induce restless legs syndrome: report of 3 cases from a clinical trial. J Clin Psychiatry 2006;67:1820.
7. Agargun MY, Kara H, Ozbek H, Tombul T, Ozer OA. Restless legs syndrome induced by mirtazapine. J Clin Psychiatry 2002; 63:1179.
8. Bahk WM, Pae CU, Chae JH, Jun TY, Kim KS. Mirtazapine may have the propensity for developing a restless legs syndrome? A case report. Psychiatry Clin Neurosci 2002;56:209-210.
9. Bonin B, Vandel P, Kantelip JP. Mirtazapine and restless leg syndrome: a case report. Therapie 2000;55:655-656.
10. Chang CC, Shiah IS, Chang HA, Mao WC. Does domperidone potentiate mirtazapine-associated restless legs syndrome? Prog Neuropsychopharmacol Biol Psychiatry 2006;30:316-318.
11. Teive HA, de Quadros A, Barros FC, Werneck LC. Worsening of autosomal dominant restless legs syndrome after use of mirtazapine: case report. Arq Neuropsiquiatr 2002;60:1025-1029.
12. Markkula J, Lauerma H. Mianserin and restless legs. Int Clin Psychopharmacol 1997;12:53-58.
13. Paik IH, Lee C, Choi BM, Chae YL, Kim CE. Mianserin-induced restless legs syndrome. Br J Psychiatry 1989;155:415-417.
14. Kim SW, Shin IS, Kim JM, Yang SJ, Shin HY, Yoon JS. Bupropion may improve restless legs syndrome: a report of three cases. Clin Neuropharmacol 2005;28:298-301.
15. Ohayon MM, Roth T. Prevalence of restless legs syndrome and periodic limb movement disorder in the general population. J Psychosomatic Res 2002;53:547-554.
16. Brown LK, Dedrick DL, Doggett JW, Guido PS. Antidepressant medication use and restless legs syndrome in patients presenting with insomnia. Sleep Med 2005;6:443-450.
17. Leutgeb U, Martus P. Regular intake of non-opioid analgesics is associated with an increased risk of restless legs syndrome in patients maintained on antidepressants. Eur J Med Res 2002;7:368-378.
18. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. Sleep Med 2003;4:101-119.
19. Bourguet CC, Ober SK, Panzner MP, Baughman KR. Evaluation of a screening interview for restless legs syndrome. Acta Neurol Scand. (Epub ahead of print).
20. Kessler RC, Andrews G, Mroczek D, Ustun B, Wittchen HU. The world health organization composite international diagnostic interview short form (CIDI-SF). Int J Methods Psychiatr Res 1998;7:171-185.
21. Bastien CH, Vallieres A, Morin CM. Validation of the insomnia severity index as an outcome measure for insomnia research. Sleep Med 2001;2:297-307.
22. Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol 2005;162: 199-200.
23. SAS 9.1. Cary, NC: 2002.
24. Riedel WJ, Eikmans K, Heldens A, Schmitt JA. Specific serotonergic reuptake inhibition impairs vigilance performance acutely and after subchronic treatment. J Psychopharmacol 2005;19:12-20.
25. Schmitt JA, Ramaekers JG, Kruizinga MJ, van Boxtel MP, Vuurman EF, Riedel WJ. Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man. J Psychopharmacol 2002;16:207-214.
26. Michaud M, Dumont M, Selmaoui B, Paquet J, Fantini ML, Montplaisir J. Circadian rhythm of restless legs syndrome: relationship with biological markers. Ann Neurol 2004;55:372-380.
27. Zhou FC, Lesch KP, Murphy DL. Serotonin uptake into dopamine neurons via dopamine transporters: a compensatory alternative. Brain Res 2002;942:109-119.
28. Zhou FM, Liang Y, Salas R, Zhang L, De Biasi M, Dani JA. Corelease of dopamine and serotonin from striatal dopamine terminals. Neuron 2005;46:65-74.
29. Dluzen D, Horstink M. Estrogen as neuroprotectant of nigrostriatal dopaminergic system: laboratory and clinical studies. Endocrine 2003;21:67-75.
30. Tsang KL, Jiang H, Ramsden DB, Ho SL. The use of estrogen in the treatment of Parkinson's disease. Parkinsonism Relat Disord 2001;8:133-137.
31. Shulman LM. Is there a connection between estrogen and Parkinson's disease? Parkinsonism Relat Disord 2002;8:289-295.
32. Thompson TL, Certain ME. Estrogen mediated inhibition of dopamine transport in the striatum: regulation by G alpha i/o. Eur J Pharmacol 2005;511:121-126.